StemCell Therapy

This article was originally published here

Curr Pharm Des. 2020 Nov 1. doi: 10.2174/1381612826666201102102233. Online ahead of print.

ABSTRACT

MicroRNAs represent a class of small (19-25 nucleotides) single-strand pieces of RNA, that are non-coding ones. They are synthesized by RNA polymerase II from transcripts which fold back on themselves. They mostly act as gene regulatory agents, that pair with complementary sequences on mRNA and produce silencing complexes, which in turn suppress coding genes at a post-transcriptional level. There is now evidence that microRNAs may affect insulin secretion or insulin action, as they can alter pancreatic beta cells development, insulin production, as well as insulin signalling. Any molecular disorder that affects these pathways can deteriorate insulin resistance and lead to type 2 diabetes mellitus (T2DM) onset. Furthermore, the expression of several microRNAs is up- or down-regulated in the presence of diabetic microvascular complications (i.e. peripheral neuropathy, nephropathy, retinopathy, foot ulcers), as well as in patients with coronary heart disease, stroke, and peripheral artery disease. However, more evidence is needed, specifically regarding T2DM patients, to establish the use of such microRNAs as diagnostical biomarkers or therapeutic targets in daily practice.

PMID:33138753 | DOI:10.2174/1381612826666201102102233

See the rest here:
The role of microRNAs in the development of type 2 diabetes complications - DocWire News

This entry was posted on November 3, 2020 at 6:58 pm and is filed under Diabetes. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |